News by subject: TRI

?CM-101 Phase 2 Trial for the Treatment of Primary Sclerosing Cholangitis (PSC) Has Completed Patient Enrollment with Topline Data Expected Midyear 2024? ?New CM-101 Patents Granted by Brazil and Israel Provide Additional Protections for Composition...

If approved, vorasidenib would be the first targeted therapy in IDH-mutant diffuse glioma, a malignant and incurable brain tumor In clinical studies, vorasidenib has demonstrated strong blood-brain barrier penetrance alongside clinically meaningful...

The data, published in the International Journal of Molecular Sciences, demonstrate that opaganib significantly improved long-term survival in an in vivo model of lung damage following exposure to ionizing radiation  Opaganib is the first selective...

Iterion Therapeutics, an oncology-focused biopharmaceutical company developing small molecule inhibitors of Transducin beta-like protein 1 (TBL1), a downstream target in the Wnt/beta-catenin signaling pathway, announced today it is actively enrolling...

Kimera® Labs Inc, a privately held clinical stage biotechnology company, is pleased to announce the first-ever publication of exosomes and a novel neural delivery breakthrough method in the prestigious Nature family of scientific journals. The...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today...

Rebamipide may be useful for rehabilitation of patients with SARS-CoV-2 post-COVID syndrome according to new research being presented at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Washington, DC, this month....

Renowned allergist Dr. Robert A. Wood, MD FAAAAI, will present detailed findings from a Phase 3 clinical trial that will have significant impact in the world of food allergy on Sunday, February 25 during a late breaking symposium during the 2024...

? A total of 17 accepted abstracts, including nine oral presentations and eight posters, reinforce AbbVie's commitment to produce a portfolio of products that aim to improve the lives of patients living with inflammatory bowel diseases (IBD)? Oral...

An HKUST-led international research collaboration has achieved a significant milestone in Alzheimer's disease (AD) diagnosis and management....

Neurophth Therapeutics, Inc. ("Neurophth") announced today that the last patient has been enrolled in Phase I/II clinical trial of Opvika® (Esonadogene Imvoparvovec) for the treatment of Leber hereditary optic neuropathy caused by ND4 mutation...

Cellenkos® today announced encouraging safety data from its innovative CK0803 neurotrophic T regulatory (Treg) cell therapy, being developed to help treat individuals with Amyotrophic Lateral Sclerosis (ALS). The company can now begin treating the...

Jacobio Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced it received approval of registrational phase III clinical trial of the combination therapy between its novel KRAS G12C inhibitor glecirasib...

Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate small amounts of peanut, milk, egg and cashew...

Anju Software, a leading provider of software solutions for the life sciences industry, is pleased to announce its participation in EUCROF's (the European CRO Federation) annual conference. Elke Ydens, Associate Director of Business Solutions at...

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a groundbreaking study published in the Journal for...

Fusion Pharmaceuticals Inc. , a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that it has entered into an exclusive worldwide license agreement with Heidelberg...

Periodontitis (PD) is a common complication in individuals with diabetes mellitus (DM). Despite the profound implications for overall health, the complex bidirectional relationship between them lacks a comprehensive understanding so far, leaving the...

BioLineRx Ltd. , a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that new post-hoc subgroup analyses and pharmacodynamic data will be presented on...

IFPA Forum Asia 2023, held in Singapore, brought together a diverse group of stakeholders, including patient advocates, their associations, family members, policymakers, healthcare professionals, and the private sector. Held in Singapore, the forum...

SciBase Holding AB ("SciBase") (STO:SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today the publication of the first direct comparison between electrical impedance spectroscopy (EIS) using Nevisense...

Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted priority review for the company's Supplemental New...

Avidity Biosciences, Inc. , a biopharmaceutical company...

Qualitas Health, LLC (dba iwi life) The results of a new clinical trial show evidence that the microalgae-derived AlmegaPL®, the foundational ingredient produced by iwi lifetm, delivers clinically relevant results decreasing triglycerides by 14% and...

HealthBioAI, a recently launched precision immunology company advancing new science for neglected immune-mediated diseases, today announced that the company's clinical trial design to investigate the treatment of patients with Long COVID/Post-Acute...

Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies today announced a new clinical collaboration designed to evaluate and combine DF1001, a HER-2 immune engager developed using Dragonfly's TriNKET...

Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study. The PROHEAR-Study is a...

The natural aging process often results in a notable reduction of muscle mass, particularly in the lower limbs. This decline, in turn, leads to a gradual decrease in physical activity among older adults, as the weakening of lower-limb muscles...

Today, Baszucki Group announced the launch of a new partnership with McLean Hospital in Belmont, MA, on a clinical trial of a therapeutic ketogenic diet for bipolar disorder. A cross-disciplinary team at McLean's early psychosis program will...

AMO Pharma Limited ("AMO Pharma"), a privately held clinical-stage specialty biopharmaceutical company focusing on rare genetic disorders with limited or no treatment options, today announced a collaboration with Population Health Research Institute...

Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced the initiation of its Phase II randomized, single-dose,...

Filament Health Corp.  (Cboe CA: FH) ("Filament" or the "Company"), a clinical?stage natural psychedelic drug development company, today announced that it has successfully completed an export of PEX010, the Company's botanical psilocybin drug...

iNtRON Biotechnology ("iNtRON", www.intodeworld.com) has announced today that New Drug Part has secured a potent anti-cancer candidate, PHAGERIA®, with broad antimicrobial activity against ETBF (Enterotoxigenic B. fragilis), a harmful microbe...

Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced today that the first patient has been dosed with the study drug in a...

AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (Together AusperBio), a...

Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing medicines targeting metalloenzymes, and Zoetis, the world's leading animal health company, announced today a collaboration to discover and develop...

UroMems, a global company developing innovative, mechatronics technology to treat stress urinary incontinence (SUI), announced today that it has successfully met the six-month primary endpoint for the first-ever female patient implanted with the...

Apex Labs Ltd. (APEX or the Company), a pharmaceutical company transforming the standard of mental health care with psilocybin is pleased to announce the approval by Health Canada of APEX's Controlled Drugs and Substances Dealer's Licence (DL). The...

In this free webinar, learn about the developments in cancer immunotherapy targeting CC chemokine receptor 9 (CCR9), a potential breakthrough for T-cell acute lymphoblastic leukemia (T-ALL). CCR9 is a potential cancer immunotherapy target, expressed...

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") , a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today announced the resubmission of the Company's Biologics...

ProJenX, a clinical-stage biotechnology company developing novel, brain-penetrant therapies targeting biologically-defined pathways for the treatment of amyotrophic lateral sclerosis (ALS) and other debilitating brain diseases, today announced that...

Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, is pleased to announce its role at the 4th Annual Gene Therapy Comparability Summit taking place February 13-15, 2024, in...

Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology to expand applications of RNA vaccines and other treatments, today shared positive results from the Phase 1...

Flamingo Therapeutics ("Flamingo") today announced that the first patient has been dosed in its PEMDA-HN trial evaluating danvatirsen in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with recurrent/metastatic head...

Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that disease education and data from the Phase 2b study of rocatinlimab (AMG451/KHK4083), an investigational product being studied in patients with moderate-to-severe atopic dermatitis, will be...

The CHU Sainte-Justine Foundation invites media representatives to attend the Sainte-Justine Winter Triathlon, a Nordic challenge that each year brings together the business community around a single goal: to actively support CHU Sainte-Justine's...

Oncolytics Biotech® Inc. , a clinical-stage immunotherapeutics company focused on oncology, today announced the expansion of enrollment for the anal cancer cohort of the GOBLET study evaluating pelareorep in combination with atezolizumab...

Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") today announced that it has entered into a drug discovery collaboration and option agreement with Shattuck Labs, Inc. (Austin, Texas, USA; CEO: Taylor Schreiber;...

GC Biopharma (CEO, Eun-Chul Huh), a South Korean biopharmaceutical company, announced on Feb. 14th that it has presented the development updates on its LSD (Lysosomal Storage Diseases) medicines at the WORLDSymposium 2024 held on Feb. 4th-9th, 2024...

Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its TEAD programme has been selected for a late-breaking presentation at the American Association for Cancer Research's Annual Meeting 2024. The conference will...